NEW YORK, NY--(Marketwire - Dec 16, 2011) - Unlike most of the so-called "recession proof" healthcare sector, the medical equipment and supplies industry has underperformed the S&P 500 by a rather large margin this year. Down more than 18 percent over the last year, medical supply makers are seeing their margins squeezed as President Obama's healthcare reform and increased regulation is threatening the industry's pricing environment. The Bedford Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Allezoe Medical Holdings, Inc. (OTCBB: [ ALZM ]) and Medtronic, Inc. (NYSE: [ MDT ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/ALZM ]

[ www.bedfordreport.com/MDT ]

Medtronic, Inc. is the global leader in medical technology and is engaged in research, design, manufacture and sale of products to alleviate pain, restore health and extend life. Earlier this week the Justice Department announced that Medtronic has agreed to pay $23.5 million to settle accusations that it paid kickbacks to doctors to implant its pacemakers and defibrillators.

Medtronic was accused of using two postmarket studies and two device registries as vehicles to pay illegal kickbacks to doctors. Medtronic paid doctors a fee of roughly $1,000 to $2,000 a patient. The government contended that Medtronic had solicited doctors for the studies to get them to use its devices, AP reports.

The Bedford Report releases stock reports on the Medical Equipment & Supplies Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.

Allezoe Medical Holdings, Inc., a biomedical company, develops, patents, and sells portable hypothermic, oxygenated preservation, and transport technology for human organs. In September Allezoe announced that its wholly owned subsidiary SureScreen Medical will be responsible for taking Allezoe's HPV diagnostic technology through the appropriate trials and federal clearances.

HPV is linked to a number of cancers in both men and women. Allezoe argues that given the size and scope of the technology's applications, "a subsidiary is appropriate to orchestrate the process."

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ http://www.bedfordreport.com/disclaimer ]